Abstract
With the release of Regulation 1394/2007, a new framework for gene and cell therapy medicinal products and tissue-engineered products was established in the European Union. For all three product classes, called advanced therapy medicinal products, a centralised marketing authorisation became mandatory. The European Medicines Agency (EMA) together with its Committee for Advanced Therapies, Committee for Human Medicinal Products and the network of national agencies is responsible for scientific evaluation of the marketing authorisation applications. For a new application, data and information relating to manufacturing processes and quality control of the active substance and the final product have to be submitted for evaluation together with data from non-clinical and clinical safety and efficacy studies. Technical requirements for ATMPs are defined in the legislation, and guidance for different products is available through several EMA/CAT guidelines. Due to the diversity of ATMPs, a tailored approach for regulating these products is considered necessary. Thus, a risk-based approach has been introduced for ATMPs allowing flexibility for the regulatory requirements. Since the regulatory framework for ATMPs was established, five products have been licenced in the European Union. However, the pipeline of new ATMPs is much bigger, as seen from the significant numbers of different products discussed by the CAT in scientific advice and classification procedures. In 2013, a public consultation on the ATMP Regulation was conducted by the European Commission, and the results were published in 2014. The report proposes several improvements for the current framework and established procedures for the regulation of ATMPs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Commission Directive 2003/63/EC amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (2003). Off J L159:46–94
Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (2007). Off J L324:121–137
Commission Directive 2009/120/EC of amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (2009). Off J L243:3–12
EMA/CAT/CPWP Guideline on the risk-based approach according to annex I, part IV of Directive 2001/83/EC applied to advanced therapy medicinal products (EMA/CAT/CPWP/686637/2011). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139748.pdf
CHMP Guideline on safety and efficacy follow-up—risk management of advanced therapy medicinal products (EMEA/149995/2008). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500006326.pdf
Report from the Commission to the European Parliament and the Council in accordance with Article 25 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/health/files/advtherapies/2014_atmp/atmp_en.pdf
EU guidelines for good manufacturing practice for medicinal products for human and veterinary use: Annex 2: manufacture of biological active substances and medicinal products for human use (2012). http://ec.europa.eu/health/files/eudralex/vol-4/vol4-an2__2012-06_en.pdf
Detailed guidelines on good clinical practice specific to Advanced Therapy Medicinal Products (2009). http://ec.europa.eu/health/files/eudralex/vol-10/2009_11_03_guideline.pdf
EMA/CAT scientific guidelines applicable to cell-based medicinal products. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000405.jsp&mid=WC0b01ac058002958a
EMA/CAT scientific guidelines applicable to gene therapy medicinal products. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000410.jsp&mid=WC0b01ac058002958d
Directive 2004/23/EC of the European Parliament and of the Council on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells (2004). Off J L102:48–58
Commission Directive 2006/17/EC implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells (2006). Off J L38:40–52
Commission Directive 2006/86/EC implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing preservation, storage and distribution of human tissues and cells (2006). Off J L294:32–50
Commission Directive 2005/61/EC implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events (2005). Off J L256:32–40
Commission Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC (2001). Off J L106:1–38
EMEA/CHMP/GTWP/125491/2006 Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003964.pdf
Council Directive 93/42/EEC concerning medical devices (1993). Off J L169:1–60
Council Directive 90/385/EC on the approximation of the laws of the Member States relating to active implantable medical devices. Off J L189:17–52
EC website on revision of the medical device directives. http://ec.europa.eu/health/medical-devices/documents/revision/index_en.htm
Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:033:0030:0040:EN:PDF
Directive 2004/33/EC implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:091:0025:0039:EN:PDF
Directive 2005/61/EC implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:256:0032:0040:EN:PDF
EMEA/CHMP/CPWP Guideline on Human Cell-based Medicinal Products EMEA/CHMP/410869/2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003894.pdf
EMA/CHMP/BWP/3088/99 Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003987.pdf
EMA/CHMP/BWP scientific guidelines addressing Adventitious Agents Safety Evaluation and Viral Safety. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000351.jsp&mid=WC0b01ac058002956c#AdventitiousAgentsSafetyEvaluationViralSafety
Ph.Eur. General Chapter on raw materials for production of ATMPs. October 2014 PharmEuropa 26.4.
CHMP guideline on plasma derived medicinal products EMA/CHMP/BWP/706271/2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109627.pdf
EMA/CAT/190186/2012 Reflection paper on management of clinical risks deriving from insertional mutagenesis. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/08/WC500147014.pdf
EMA/CAT/GTWP/44236/2009 Reflection paper on design modifications of gene therapy medicinal products during development. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500122743.pdf
CHMP guideline on environmental risk assessments for medicinal products consisting of, or containing, Genetically Modified Organisms (GMOs) EMEA/CHMP/BWP/473191/2006 – Corr. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003805.pdf
EMA/CAT Summaries of scientific recommendations on classification of advanced-therapy medicinal products. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000301.jsp&mid=WC0b01ac05800862c0
EMA/CHMP scientific guidelines for non-clinical studies. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000083.jsp&mid=WC0b01ac0580027548
Reinhardt J, Flory E, Büttel I, Schröder C, Fricke S, Vucinic V, Cross M, Niederwieser D (2013) MSCs: clinical application and EU regulatory aspects. In: Stem cell biology and regenerative medicine. Springer, New York
Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R (2003) Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101:2999–3001
Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169:12–20
Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors (EMEA/CHMP/273974/2005). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003982.pdf
Directive 2001/20/EC of the European parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J L121:34–44
Barkholt L, Flory E, Jekerle V et al (2013) Risk of tumorigenicity in mesenchymal stromal cell-based therapies—bridging scientific observations and regulatory viewpoints. Cytotherapy 15(7):753–759
ICH E8 General Considerations for Clinical Trials (1997). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf
EMA/CHMP Scientific guidelines for efficacy and safety. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000085.jsp&mid=WC0b01ac0580027549
EMEA/CHMP/SWP/28367/07 Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products (2007). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf
EMA/CHMP/205/95 Guideline on the evaluation of anticancer medicinal products (2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf
EMA/CAT/CPWP/573420/2009 Reflection paper on clinical aspects related to tissue engineered products (draft). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/04/WC500125446.pdf
Quyyumi AA, Waller EK, Murrow J, Esteves F, Galt J, Oshinski J et al (2011) CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 161(1):98–105
Sauer AV, Di Lorenzo B, Carriglio N, Aiuti A (2014) Progress in gene therapy for primary immunodeficiencies using lentiviral vectors. Curr Opin Allergy Clin Immunol 14(6):527–534
Ehrlich HJ, Wong WY, Ewenstein BM, Dockal M, Turecek PL, Gringeri A et al (2013) Development of novel treatment options for patients with haemophilia. Hamostaseologie; 33(Suppl 1):S36–S38
Glybera, European Public Assessment Report (2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002145/human_med_001480.jsp&mid=WC0b01ac058001d124
ChondroCelect, European Public Assessment Report (2009). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000878/human_med_000698.jsp&mid=WC0b01ac058001d124
MACI, European Public Assessment Report (2013). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002522/human_med_001660.jsp&mid=WC0b01ac058001d124
Provenge, European Public Assessment Report (2013). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002513/human_med_001680.jsp&mid=WC0b01ac058001d124
CAT monthly report of application procedures, guidelines and related documents on advanced therapies, May 2015 meeting. http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2015/05/WC500187397.pdf
Maciulaitis R, D’Apote L, Buchanan A, Pioppo L, Schneider CK (2012) Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol Ther 20(3):479–482
Regulation (EU) No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (2014). Off J L158:1–76. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2014.158.01.0001.01.ENG
Reischl I, Menezes-Ferreira M (2013) Advanced therapy medicinal products for whom? The different facets of hospital exemption. Regul Rapporteur 10:11–13
European Commission, Directorate General Health and Consumers, Pharmaceutical Unit. Summary of the responses to the public consultation on the Regulation on Advanced Therapies, 22 May 2013. http://ec.europa.eu/health/files/advtherapies/2013_05_pc_atmp/2013_04_03_pc_summary.pdf
Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (2001). Off J L 11:67
Holoclar, European Public Assessment Report (2015) http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002450/human_med_001844.jsp&mid=WC0b01ac058001d124
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 American Society of Gene and Cell Therapy
About this chapter
Cite this chapter
Salmikangas, P. et al. (2015). Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. In: Galli, M., Serabian, M. (eds) Regulatory Aspects of Gene Therapy and Cell Therapy Products. Advances in Experimental Medicine and Biology(), vol 871. Springer, Cham. https://doi.org/10.1007/978-3-319-18618-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-18618-4_6
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18617-7
Online ISBN: 978-3-319-18618-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)